We’ve recently updated our valuation analysis.

Atreca Valuation

Is BCEL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BCEL?

Other financial metrics that can be useful for relative valuation.

BCEL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDA-0.4x
PEG Ration/a

Price to Book Ratio vs Peers

How does BCEL's PB Ratio compare to its peers?

The above table shows the PB ratio for BCEL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average0.5x
SPRB Spruce Biosciences
0.8x36.4%US$60.3m
RPHM Reneo Pharmaceuticals
0.5x62.6%US$59.9m
SURF Surface Oncology
0.6x1.1%US$62.4m
CNTB Connect Biopharma Holdings
0.3x-1.0%US$61.6m
BCEL Atreca
0.6x13.8%US$60.2m

Price-To-Book vs Peers: BCEL is expensive based on its Price-To-Book Ratio (0.6x) compared to the peer average (0.5x).


Price to Earnings Ratio vs Industry

How does BCEL's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a14.1%
n/an/an/a

Price-To-Book vs Industry: BCEL is good value based on its Price-To-Book Ratio (0.6x) compared to the US Biotechs industry average (1.8x)


Price to Book Ratio vs Fair Ratio

What is BCEL's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BCEL PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.6x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate BCEL's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BCEL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BCEL's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BCEL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.58
US$11.44
+624.3%
63.0%US$25.00US$2.00n/a9
Jan ’24US$0.80
US$12.75
+1,492.6%
60.2%US$25.00US$2.00n/a8
Dec ’23US$1.04
US$12.56
+1,107.3%
57.8%US$25.00US$2.00n/a9
Nov ’23US$1.51
US$14.11
+834.5%
42.1%US$25.00US$4.00n/a9
Oct ’23US$1.57
US$14.11
+798.8%
42.1%US$25.00US$4.00n/a9
Sep ’23US$1.81
US$14.11
+679.6%
42.1%US$25.00US$4.00n/a9
Aug ’23US$1.95
US$14.89
+663.5%
42.5%US$25.00US$4.00n/a9
Jul ’23US$1.79
US$14.89
+731.8%
42.5%US$25.00US$4.00n/a9
Jun ’23US$1.59
US$14.89
+836.4%
42.5%US$25.00US$4.00n/a9
May ’23US$1.96
US$18.67
+852.4%
39.6%US$35.00US$11.00n/a9
Apr ’23US$3.09
US$18.67
+504.1%
39.6%US$35.00US$11.00n/a9
Mar ’23US$1.89
US$19.56
+934.7%
39.0%US$35.00US$11.00n/a9
Feb ’23US$2.15
US$21.67
+907.8%
35.1%US$35.00US$12.00n/a9
Jan ’23US$3.03
US$21.67
+615.1%
35.1%US$35.00US$12.00US$0.809
Dec ’22US$3.38
US$21.67
+541.0%
35.1%US$35.00US$12.00US$1.049
Nov ’22US$6.29
US$21.67
+244.5%
35.1%US$35.00US$12.00US$1.519
Oct ’22US$6.12
US$21.67
+254.0%
35.1%US$35.00US$12.00US$1.579
Sep ’22US$6.34
US$21.67
+241.7%
35.1%US$35.00US$12.00US$1.819
Aug ’22US$5.49
US$22.00
+300.7%
35.9%US$35.00US$12.00US$1.959
Jul ’22US$8.65
US$29.89
+245.5%
9.9%US$35.00US$25.00US$1.799
Jun ’22US$9.18
US$30.22
+229.2%
9.2%US$35.00US$25.00US$1.599
May ’22US$11.94
US$30.22
+153.1%
9.2%US$35.00US$25.00US$1.969
Apr ’22US$13.69
US$30.22
+120.8%
9.2%US$35.00US$25.00US$3.099
Mar ’22US$18.35
US$30.00
+63.5%
9.3%US$35.00US$25.00US$1.899
Feb ’22US$13.82
US$29.75
+115.3%
9.9%US$35.00US$25.00US$2.158
Jan ’22US$16.15
US$29.75
+84.2%
9.9%US$35.00US$25.00US$3.038

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies